



PATIENT DETAILS

Name: JANNY DOE **Laboratory Accession:** 12345-21-321-1113
MRN: 999888777 **Tumor tissue:** Bronchus and lung cancer
DOB: 12/11/1954 **Gender:** Female **Diagnosis:** 254626006 - Adenocarcinoma of lung

MOLECULAR TUMOR BOARD INTERPRETATION

Ranking	Therapy	Target Gene	Aberration Type
1	Osimertinib	EGFR	p.E746_A750del

COMMENTS

The exon 19 deletion in EGFR seen here is predictive of a high likelihood of response to tyrosine kinase inhibitors such as osimertinib.

IMMUNOTHERAPY FINDINGS

Biomarker	Alteration	Therapy
MSI	Stable 4.2% Unstable Sites	
TMB	Low 6.3 muts/Mb	
PD-L1	TPS: less than 1%	

PERTINENT NEGATIVES (Disease-relevant genes not containing detected mutations)

ALK, ROS1, BRAF, ERBB2, KIT, KRAS, MET, NRAS, NTRK1, NTRK2, NTRK3, PIK3CA, PTEN, RET,



CLINICALLY RELEVANT MUTATIONS

Gene	Mutation	FDA approved within indication	FDA approved outside of indication	Guidelines	Clinical Trials
EGFR	p.E746_A750del	Bevacizumab + Erlotinib, Afatinib + Cetuximab, Erlotinib, Afatinib, Erlotinib + Ramucirumab, Osimertinib, Dacomitinib, Gefitinib	None	Yes	19
EGFR	Copy number gain in EGFR (5 copies)	None	Necitumumab + Gemcitabine + Cisplatin, Afatinib, Neratinib		4
TP53	p.K132N	None	None		1
FAT1	p.F614_F615delinsLC	None	None		No



ADDITIONAL INFORMATION



The therapy match and recommendations in this report are for informational purposes only and should not be considered an attempt to practice medicine. This guidance is based purely on analysis of laboratory test results and not from any interaction with the patient. The selection of any, all, or none of the therapies referenced in this report resides entirely within the discretion of the treating physician, taking into consideration all relevant information concerning the patient and the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the applicable standard of care. The recommendations in this report are not intended to replace or overrule the professional medical judgment of the treating physician.

The recommendations in this report were made by individual members of the molecular tumor board and are current as of the date of this report. Other medical professionals may offer different recommendations based on their review of the analytic results set forth in this report. Intermountain Precision Genomics is not under any obligation to issue an updated report.